September 02, 2014 9:08 PM ET


Company Overview of BioMotiv, LLC

Company Overview

BioMotiv, LLC develops medicines for patients. It develops various types of therapeutics, such as small molecules, antibodies, proteins, cell therapies, and nucleotides. BioMotiv, LLC was formerly known as BIOU, LLC. The company was founded in 2012 and is based in Cleveland, Ohio.

3605 Warrensville Center Road

Cleveland, OH 44122-2394

United States

Founded in 2012



Key Executives for BioMotiv, LLC

Chief Executive Officer and Member of Board of Managers
Age: 42
Senior Vice President
Vice President of Business Development
Chairman of Scientific Advisory Board
Age: 65
Compensation as of Fiscal Year 2014.

BioMotiv, LLC Key Developments

BioMotiv to Develop BioAtla's TH22 Pathway-Directed Antibody for treatment of inflammatory bowel diseases and oncologic indications

BioAtla has licensed exclusive worldwide rights to BioMotiv to develop and commercialize its TH22 pathway-directed antibody compound for the treatment of inflammatory bowel diseases (IBD) and oncologic indications. In conjunction with the licensing deal, BioMotiv has established Kodosil Bio which will develop all compounds resulting from the license. BioAtla used its Comprehensive Integrated Antibody Optimization (CIAO!) platform for the identification, humanization and optimization of the monoclonal antibody. The platform selects candidates with natural protein folding and glycosylation, high protein expression and faster downstream process development characteristics, providing cost and time efficiencies all through the development process. Under the deal, BioAtla will provide its discovery and preclinical development processes for the licensed compounds, while Kodosil Bio will manage the development of the therapeutic antibody and will fund all discovery and development activities through clinical proof-of-concept.

BioMotive Presents at Life Sciences Summit 2013, Nov-21-2013 04:30 PM

BioMotive Presents at Life Sciences Summit 2013, Nov-21-2013 04:30 PM. Venue: Convene - Midtown East, 730 Third Avenue (Between East 45th and 46th Streets), 17th Floor, New York, NY 10017, United States. Speakers: Terry C. Vance, Chief Business Officer.

Torrey Pines Signs Investment Agreement with BioMotiv

Torrey Pines Investment has signed an investment agreement with BioMotiv.

Similar Private Companies By Industry

Company Name Region
Montigen Pharmaceuticals Inc. United States
ChiRhoClin, Inc. United States
DermAvance Pharmaceuticals, Inc. United States
AnaBios Corporation, Inc. United States
Bergstrom Nutrition, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BioMotiv, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at